February 1, 1993Stroke
Increased thromboxane biosynthesis in patients with acute cerebral ischemia.
Why the study?
Is thromboxane biosynthesis increased in patients with acute cerebral ischemia, and is it suppressible by low-dose aspirin?
Population
71 patients, comprising 51 with acute cerebral ischemia and 20 control patients with nonvascular…
Comparison
Measurement of urinary excretion of… vs Control patients with nonvascular neurological…
Design
Case-control
Follow-up
7 days for the aspirin subset
Authors
Discussion
Loading...
Member takes
Implication
Elevated thromboxane in acute stroke may be aspirin-suppressible; leaves open its value for guiding therapy or risk stratification.
Structured PICO
Is thromboxane biosynthesis increased in patients with acute cerebral ischemia, and is it suppressible by low-dose aspirin?
P
Population
71 patients, comprising 51 with acute cerebral ischemia (14 transient ischemic attack, 37 ischemic stroke) and 20 control patients with nonvascular neurological disorders. Median time between symptom onset and urine sampling was 24 hours.
I
Intervention
Measurement of urinary excretion of 11-dehydro-thromboxane B2; a subset of 11 stroke patients received low-dose aspirin (50 mg per day for 7 days).
C
Comparator
Control patients with nonvascular neurological disorders.
O
Outcome
Urinary excretion rate of immunoreactive 11-dehydro-thromboxane B2.surrogate
Thromboxane biosynthesis is significantly increased during the early phase of acute ischemic stroke and can be suppressed by low-dose aspirin, providing a mechanistic rationale for its use.
Cite This Study
Koudstaal et al. (1993) studied this question.